425P - Clinicopathological factors associated with postoperative survival in patients undergoing lobectomy with pathological stage IB non-small-cell lung...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Non-Small Cell Lung Cancer
Surgical Oncology
Presenter Masanori Shimomura
Citation Annals of Oncology (2016) 27 (suppl_9): ix134-ix135. 10.1093/annonc/mdw592
Authors M. Shimomura, S. Ishihara
  • General Thoracic Surgery, Ayabe city hospital, 623-0011 - Ayabe/JP

Abstract

Background

The treatment outcomes of patients with non-small-cell lung cancer have improved because of advances in diagnostic imaging and multidisciplinary therapies. However, the reported 5-year survival rate of patients with pathological stage IB non-small-cell lung cancer is approximately only 60%. We evaluated the clinicopathological factors associated with postoperative survival in patients with pathological stage IB non-small-cell lung cancer.

Methods

From July 2006 through July 2014, 40 patients with pathological stage IB non-small-cell lung cancer underwent lobectomy and mediastinal lymph node dissection. We retrospectively evaluated the factors of age, sex, preoperative carcinoembryonic antigen level, pathological classification, tumor diameter, Epidermal growth factor receptor (EGFR) mutation, and pleural, lymph duct, and venous invasion.

Results

The 5-year survival rates of the overall cohort were 63.4%. The overall survival rate at 2 years was 34.3% among the patients with squamous cell carcinoma, 83.4% among the patients with non-squamous cell carcinoma. Further analysis revealed that the 5-year survival rates of patients with v1 and v0 invasion were 18.6% and 56.8%, respectively. A survival analysis revealed that both squamous cell carcinoma and v1 venous invasion were associated with poor prognosis.

Conclusions

Patients with pathological stage IB non-small-cell lung cancer classified as squamous cell carcinoma and those with v1 invasion have a higher risk of recurrence.

Clinical trial indentification

Legal entity responsible for the study

Ayabe City, Kyoto, Japan

Funding

Ayabe City Hospital

Disclosure

All authors have declared no conflicts of interest.